Loading
Cancer Treatment and Pharmacology · Journal article
Frontiers in Neurology · September 10, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes preclinical and clinical evidence on acupuncture for chemotherapy-induced peripheral neuropathy, a condition affecting 20–85% of cancer patients with no disease-modifying therapies. While sham-controlled trials suggest manual acupuncture and electroacupuncture may alleviate pain and sensory symptoms, proposed mechanistic pathways remain largely unconfirmed, and clinical translation is hindered by methodological heterogeneity and inadequate patient stratification. The evidence is exploratory rather than conclusive.
Narrative review. Chemotherapy-induced peripheral neuropathy in cancer patients; review includes preclinical CIPN studies and clinical sham-controlled trials.. Intervention: Acupuncture modalities (manual acupuncture, electroacupuncture, auricular acupuncture, ALTENS, Scrambler therapy) and combination therapies.. Compared with: Sham acupuncture (in clinical trials); no active comparator specified..
CIPN affects 20–85% of cancer patients and currently lacks disease-modifying therapies Sham-controlled trials suggest manual acupuncture and electroacupuncture may alleviate pain, sensory symptoms, and quality-of-life impairment High response rates for auricular acupuncture derive from uncontrolled case series only
Safety profiles are generally favorable; combination studies suggest possible additive benefit rather than established synergy
Clinicians should recognize that while sham-controlled evidence supports some symptom relief from acupuncture modalities in CIPN, the mechanistic basis remains unclear and methodological limitations prevent strong recommendation. Further research with biomarkers and cost-effectiveness analysis is needed before acupuncture can be integrated into standard CIPN management.
This is a narrative review synthesizing preclinical mechanistic evidence and clinical trials of variable quality, without presenting a new primary result; it raises questions about acupuncture's role in CIPN rather than answering them with definitive data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that while sham-controlled evidence supports some symptom relief from acupuncture modalities in CIPN, the mechanistic basis remains unclear and methodological limitations prevent strong recommendation. Further research with biomarkers and cost-effectiveness analysis is needed before acupuncture can be integrated into standard CIPN management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Chemotherapy-induced peripheral neuropathy (CIPN), a debilitating dose-limiting toxicity affecting 20–85% of cancer patients, lacks disease-modifying therapies. This review synthesizes evidence supporting acupuncture as a potential multi-target strategy against CIPN. Direct preclinical CIPN studies suggest that electroacupuncture (EA) may modulate selected neuroinflammatory and oxidative pathways, including TLR4/NF-κB signaling, TRPV1 upregulation, and spinal glial activation; proposed effects on Nav1.7–1.9, PGC-1α/AMPK, or HDAC6-related microtubule stabilization remain unconfirmed. Clinically, sham-controlled trials suggest that manual acupuncture and EA may alleviate pain, sensory symptoms, and quality-of-life impairment. High response rates for auricular acupuncture derive from an uncontrolled case series, and ALTENS findings are preliminary. The MC5-A Calmare device delivers Scrambler therapy and is distinct from ALTENS and acupuncture. Combination studies suggest possible additive benefit rather than established synergy. Safety profiles are generally favorable. However, clinical translation is impeded by methodological heterogeneity, subjective “De Qi” assessment, and inadequate patient stratification. Future research should focus on trials with lab markers and cost analyses to determine how well acupuncture helps people complete their treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.